Inheriting the DNA of Dr. Shibasaburo Kitasato,
we take on the challenge of creating new value, toward
xsmb thu ghiContributing to Society through Healthcare
xsmb thu ghiPresident and CEO
I express my deepest gratitude to all our shareholders for your understanding and support of Terumo Group business activities.
Amid the terrible ravages of COVID-19, I offer my deepest condolences for the people who have passed away, and pray for a speedy recovery for all those who have been infected by the virus.
Terumo Group established a COVID-19 task force in January 2020, prior to the global spread of the virus, rapidly transitioning to a crisis management mode. As the situation has changed with dizzying speed, we have gathered information from around the world and closely coordinated with each of our sites to respond to this crisis unified as a Group. We have set the health and safety of our associates as our highest priority, raising infection prevention measures in our production sites to their strictest level as we firmly carry out our policy of continuing to "sustain healthcare".
Terumo products are making a variety of contributions in the prevention and treatment of COVID-19. Amid the infection’s spread, our thermometers enable people to monitor their body temperatures daily. Terumo ECMO (extra-corporeal membrane oxygenation) is being used in intensive care for people with severe cases. In the United States, our centrifugal apheresis systems are garnering attention for their potential use in treatment.
xsmb thu ghiDr. Shibasaburo Kitasato, one of the founding members of Terumo, dedicated his life to plague prevention and microbiological research. With a long history of striving to prevent disease, Terumo has inherited his DNA. As we prepare to celebrate the Terumo 100th founding anniversary in 2021, we take pride in our history and the spirit in which the company was founded, even as we steadily face this crisis today.
xsmb thu ghiAs societies continue to age, medical settings have no choice but to transform; we believe this transformation will be accelerated by COVID-19. To lead in this evolving healthcare environment, we too must change. For this purpose, I have designated FY2020—the fourth year of our five-year Mid- to Long-term Growth Strategy—as a "year to accelerate change and revitalization." Terumo will accelerate the utilization of its diverse talent and realize a global organizational transformation, in order to continue bringing new value to medical settings.
We ask for your continued understanding and support in this endeavor.